July 16 (Reuters) - Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among ...

Eli Lilly has struck a deal to buy psychedelic drug developer AtaiBeckley for an initial $2.8 billion, weeks after the Trump ...

FDA finalized new guidance for testing MDMA and psilocybin in trials, days after Massachusetts advanced its own psychedelic ...

News and commentary from the psychiatry world ...

AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic ...

The greatest therapeutic effects of psychedelics appear to occur long after the drug is gone. New research suggests they ...

Eli Lilly has agreed to buy a Peter Thiel-backed psychedelic drug developer for up to $3.8bn, as the world’s most valuable ...

The American drug giant will buy a psychedelic drug developer, a sign of rising interest in using the chemicals as psychiatric treatments.

Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental ...

The VA and HHS have signed an agreement to coordinate psychedelic clinical trials for veterans and accelerate research into ...

Opportunities and challenges of AI, HHS and VA team up on psychedelic treatments and a bill expands compensation for workers ...

As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have ...